BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nourianz (istradefylline) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nourianz (istradefylline)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05217498-1588@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nourianz (istradefylline): Phase 1/2 readout est. (NCT05217498)
DESCRIPTION:Nourianz (istradefylline)\, phase 1/2.\nStudy: Combining Low Ox
 ygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functiona
 l Mobility After Spinal Cord Injury\nEstimated primary completion: 30 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/istradefyl
 line#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05217498
URL:https://assetmemo.bio/drug/istradefylline#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704385-1588@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Nourianz (istradefylline): Phase 1/2 readout est. (NCT07704385)
DESCRIPTION:Nourianz (istradefylline)\, phase 1/2.\nStudy: Enhancing Rehabi
 litation in Aging Study (ERAS)\nEstimated primary completion: 31 May 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/istradefylline#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07704385
URL:https://assetmemo.bio/drug/istradefylline#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
